Capital Cell Afterwork about Rare Diseases & Orphan Drugs

Paris, France – 22d May 2025

Yann GODFRIN, Ph.D., Axoltis Pharma CEO, is very delighted to join the Capital Cell Afterwork about Rare Diseases & Orphan Drugs. Also a good opportunity to present our promising drug candidate NX210c currently in a phase 2 clinical trial on ALS patients.